Changes of clotting and fibrinolytic factors levels during Danazol therapy for application of treatment of hereditary hemorrhagic disease.

Jun Yoshii, Shoko SAYAMA, K Okudera, S Yaguchi, Toshitaka Ogawa, Hiroyuki Kashiwagi, Yuriko BABA, Hiroaki Soma
In: Blood & Vessel · 1985 · vol. 16(2) , pp. 208–210 · doi:10.2491/jjsth1970.16.208 · W2330037878
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-07 ⓘ

Danazol therapy for hereditary hemorrhagic disease increased F VIII and F IX levels, transiently decreased fibrinogen, and elevated plasma kallikrein inhibitor, unlike other androgen treatments.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-29 · read from full text ⓘ

This 1985 study investigated the effects of Danazol therapy on clotting and fibrinolytic factors in women, comparing outcomes to those receiving standard androgen treatment. The researchers found that four months of Danazol administration led to steady rises in Factor VIII and Factor IX levels, alongside higher plasma kallikrein inhibitor levels during menstruation, without significant changes in platelet counts or other major fibrinolytic activities. Although in vitro tests did not show concentration-dependent changes, the authors concluded that Danazol’s distinct impact on coagulation factors makes it potentially applicable for treating hemorrhagic disorders. This paper is centrally about endometriosis — specifically noting that Danazol was used in the treatment of this condition while its effects on hemostasis were being evaluated.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Danazol, a derivative of 17α-ethinyl testosterone which is a synthetic steroid with antigonadotropic properties has been used in the treatment of endometriosis. The efficacy of Danazol due to long-term administration resulted in a reduction of menstrual blood loss. The purpose of this investigation was to study not only the influence of Danazol on clotting and fibrinolytic activities for patients with endometriosis, but also to know that Danazol therapy may decrease menstrual blood loss in patients with hereditary hemorrhagic disease as reported by Soma et al.Results: 1) There were steady rises in F VIII and F IX after 4 months administration of Danazol, while no rises of such factors were observed in women given androgen. 2) No significant increase of platelets and other clotting factors was observed during Danazol treatment, even though a transient decrease of fibrinogen was seen. 3) No significant changes of fibrinolytic activities such as α1-AT, α2-MG, AT-III and C1-INA were observed. 4) Plasma levels of kallikrein inhibitor at the onset of menstruation in women treated with Danazol was higher than the control group. 5) However, in vitro changes of clotting as well as fibrinolytic activities depending upon concentrations of Danazol were not evident.In conclusion, Danazol therapy on coagulation and fibrinolytic factors was different from the effect of Pill treatment. Therefore, it will be applicable to clinical use of the treatment of hemorrhagic disorders.
Full text 2,490 characters · extracted from oa-html · 2 sections · click to expand

Results

1) There were steady rises in F VIII and F IX after 4 months administration of Danazol, while no rises of such factors were observed in women given androgen. 2) No significant increase of platelets and other clotting factors was observed during Danazol treatment, even though a transient decrease of fibrinogen was seen. 3) No significant changes of fibrinolytic activities such as α1-AT, α2-MG, AT-III and C1-INA were observed. 4) Plasma levels of kallikrein inhibitor at the onset of menstruation in women treated with Danazol was higher than the control group. 5) However, in vitro changes of clotting as well as fibrinolytic activities depending upon concentrations of Danazol were not evident. In conclusion, Danazol therapy on coagulation and fibrinolytic factors was different from the effect of Pill treatment. Therefore, it will be applicable to clinical use of the treatment of hemorrhagic disorders.

Results

1) There were steady rises in F VIII and F IX after 4 months administration of Danazol, while no rises of such factors were observed in women given androgen. 2) No significant increase of platelets and other clotting factors was observed during Danazol treatment, even though a transient decrease of fibrinogen was seen. 3) No significant changes of fibrinolytic activities such as α1-AT, α2-MG, AT-III and C1-INA were observed. 4) Plasma levels of kallikrein inhibitor at the onset of menstruation in women treated with Danazol was higher than the control group. 5) However, in vitro changes of clotting as well as fibrinolytic activities depending upon concentrations of Danazol were not evident. In conclusion, Danazol therapy on coagulation and fibrinolytic factors was different from the effect of Pill treatment. Therefore, it will be applicable to clinical use of the treatment of hemorrhagic disorders. © 日本血栓止血学会

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK